clinical trial · NCT05953506
Phase 1a Study in Healthy Participants
Jiangsu Hansoh Pharmaceutical Co., Ltd.·phase1·unknown·n = 52
HealthyHS-10506HS-10506 Placebo
brief summary
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral HS-10506 in Chinese Healthy Subjects.
started
Jul 17, 2023
primary completion
Dec 24, 2023
completion
Dec 24, 2023
last updated
Jul 20, 2023
detailed description
This is a phase 1a, first-in-human, double-blind, placebo-controlled clinical trial. The primary objective is to assess the safety, tolerability and pharmacokinetic of single dose HS-10506 in healthy subjects. The secondary objective is to observed pharmacokinetic parameters and metabolites after single dose of HS-10506.
official title
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of HS-10506 in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol